Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Bristol-Myers Squibb CompanyNYSE: BMY

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin holds steady near 31.0%

Operating margin was 31.0% in Q2 FY2026, up 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 28.1%, up 7.3 pp year over year. Over 3 fiscal years it widened by 8.8 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 19 analysts of 33.3% for the fiscal year ending Dec 2026, up from 28.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
31.0%+1.7 pp QoQ
Last fiscal yearDec 2025
28.5%+16.3 pp YoY
LTMJun 2026
28.1%+7.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.3 pp-6.4 pp-6.7 pp
1 year+16.3 pp+4.8 pp-11.4 pp
3 years+8.8 pp+6.4 pp-2.4 pp
5 years+6.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
28.5%
Year-over-year change
+16.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How BMY compares with its peers on the latest reported figures

  • BMY's LTM Jun 2026 operating margin of 28.1% is the 5th highest of the 11 companies compared; the peer median is 26.2%.
  • Its year-over-year change of +7.3 pp is the 4th highest of 11, against a peer median of +1.1 pp.
  • Over three fiscal years its change of +8.8 pp compares with a peer median of +4.5 pp.
BMY Competitors Peer median
Operating Margin for BMY and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202649.7% +7.6 pp+15.2 pp
ABBVAbbVie Inc.LTM Sep 202635.5% +20.4 pp+1.6 pp
AMGNAmgen Inc.LTM Jun 202633.2% +9.7 pp-7.3 pp
NVSNovartis AGLTM Jun 202630.5% +0.3 pp+12.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202628.1% +7.3 pp+8.8 pp
PFEPfizer Inc.LTM Jun 202626.7% +0.6 pp-9.9 pp
JNJJohnson & JohnsonLTM Sep 202625.7% -0.4 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
GSKGSK plcLTM Jun 202620.7% +4.5 pp+3.6 pp
MRKMerck & Co., Inc.LTM Jun 202616.7% -16.9 pp+5.3 pp
GILDGilead Sciences, Inc.LTM Jun 2026-4.9% -32.8 pp+12.9 pp
Peer median (excluding BMY) 26.2%+1.1 pp+4.5 pp

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.